1378388-19-2

Basic information

• Product Name: 7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone
• Synonyms: 7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone;7-((2-Bromo-5-chlorobenzyl)oxy)-3,4-dihydronaphthalen-1(2H)-one;CL122
• CAS NO: 1378388-19-2
• Molecular Formula: C₁₇H₁₄BrClO₂
• Molecular Weight: 365.64886
• Mol File: 1378388-19-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 489.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.488±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone(1378388-19-2)
• EPA Substance Registry System: 7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone(1378388-19-2)

Safety Data

• Hazardous Substances Data: 1378388-19-2(Hazardous Substances Data)

Usage

Description

7-[(2-Bromo-5-chlorophenyl)methoxy]-3,4-dihydro-1(2H)-naphthalenone, commonly referred to as BNTX, is a synthetic compound that belongs to the 1(2H)-naphthalenone class. It features a 2-bromo-5-chlorophenyl group and a methoxy group attached to its naphthalenone core. BNTX is recognized for its potent and selective antagonism of the κ-opioid receptor, which positions it as a candidate for research and therapeutic intervention in pain management and addiction treatment.

Uses

Used in Pharmaceutical Industry:
BNTX is utilized as a κ-opioid receptor antagonist for the study and treatment of pain and addiction. Its selectivity allows it to block the effects of opioid drugs without impacting the analgesic properties of non-opioid pain medications, offering a potential advantage in managing opioid dependence and abuse.
Used in Neurological Disorders Research:
In the field of neurological disorders, BNTX is used as a research tool to explore the role of the κ-opioid receptor system in conditions such as depression and anxiety. Its modulation of this receptor system suggests potential therapeutic applications in treating these disorders, providing a new avenue for intervention and management strategies.
Used in Drug Development:
BNTX serves as a lead compound in drug development for the creation of novel medications targeting the κ-opioid receptor. Its unique properties make it a valuable asset in the design of new therapies aimed at addressing unmet needs in pain, addiction, and mental health treatment.

Upstream product

• 66192-24-3 2-bromo-5-chlorobenzyl bromide 
• 22009-38-7 7-hydroxy-1-tetralone 

Downstream Products

• 1378390-29-4 3-(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one 
• 1378390-35-2 (2S,5S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate 
• 1378390-69-2 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-methylpyrrolidine-1,2-dicarboxylate 
• 1378391-42-4 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-43-5 (2R,4R)-1-tert-butyl 2-(2-(9-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378388-20-5 3-chloro-10,11-dihydro-5H-benzo[d]naphtho[2,3-b]pyran-8(9H)-one 
• 1378391-38-8 3-(2-bromo-1-hydroxyethyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one 

Relevant articles and documents

Compound used for inhibiting hepatitis C virus, and pharmaceutical applications thereof

The invention relates to a compound which is represented by formula I, is used for inhibiting hepatitis C virus, and possesses excellent bioavailability, and a nontoxic pharmaceutically acceptable salt thereof. The compound possesses extremely high inhibition effect on HCV of all genotypes. In the formula I, R is used for representing hydrogen atom, glycyl, L-alanyl, L-leucyl, L-valyl, or L-isoleucyl.

PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS

The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.

CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.